SEMI-SOLID cloning techniques for haemopoietic cells have made it possible to identify, and to some extent characterize, specific factors stimulating or inhibiting haemopoietic cell proliferation. Agar cultures supporting neutrophilic and macrophage proliferation have been used to identify and monitor the purification of the specific glycoprotein, GM-colonystimulating factor (GM-CSF), required for the proliferation of these cells in vitro (Metcalf, 1970; Stanley and Metcalf, 1 969; Sheridan and Metcalf, 1974; Stanley et al., 1975) . Similar studies have documented the existence of different factors required for eosinophil and megakaryocyte proliferation in vitro . For erythropoietic colony formation in vitro, inclusion of erythropoietin has been shown to be essential for colony formation, which can be used as an in vitro bioassay system for erythropoietin (Stephenson et al., 1971; Iscove, Sieber and Winterhalter, 1974) .
Recently, a culture system has been developed which supports the clonal proliferation in semi-solid agar of mouse B-lymphocytes (Metcalf et al., 1975a, b) . In this system, the addition of 2-mercaptoethanol is essential for lymphocyte survival and proliferation. B-lymphocyte colony formation appears to differ from all other haemopoietic colony-forming systems in not requiring the addition of a specific growth-stimulating factor. However, this unique behaviour may be more apparent than real. The cultures exhibit a marked non-linearity between the number of cells cultured and the number of colonies developing (Metcalf et al., 1975b) . Furthermore, some evidence has been produced that 2-mercaptoethanol may induce the formation in the culture dish itself of material with stimulating or potentiating activity on B-lymphocyte colony proliferation (Metcalf, 1976) .
Based on the ability of a granulocytemacrophage colony assay system to detect and measure GM-CSF levels in human serum (Foster et al., 1968; Metcalf et al., 1971) , the present study was undertaken, to determine the effects of adding serum from normal subjects and patients with various diseases on colony formation in agar by B-lymphocytes from mouse spleen tissue. A suboptimal culture system was used deliberately, to facilitate detection of sera with colony-stimulating activity.
MATERIALS AND METHODS
Serum collection.-Using aseptic procedures, blood was collected from normal donors or patients with various diseases. Clots were allowed to retract at room temperature and the sera removed after centrifugation. Sera were stored at 400 in capped bottles and in most cases were assayed within 3 weeks of collection.
Culture 8ysteM.-All cultures were performed in 35-mm plastic Petri dishes using 1-ml volumes of agar medium. All cultures contained 25,000 spleen cells from 2-monthold C57BL mice. Cell suspensions were obtained by teasing the spleen apart with needles in Eisen's balanced salt solution, and disrupting the remaining clumps by gentle pipetting, to produce a dispersed suspension of single cells. Viable cell counts were performed using eosin.
The culture medium was prepared by mixing equal volumes of double strength Dulbecco's modified Eagle's medium and 0.6% Bacto-Agar in distilled water (Difco, Detroit, Michigan) , the latter boiled for 2 min to dissolve and sterilize the agar, then held at 37°C. The formula of the double strength medium was: Dulbecco's modified Eagle's medium HG Instant Culture Powder H-16 (10 0 g) (Grand Island Biological Company, New York); double-glass-distilled water 420 ml; 3 ml L-asparagine (20 ,ug/ml); 1'5 ml DEAE dextran (75 jg/ml) (Pharmacia, Sweden, mol. wt.= 2 x 106/n/ = 0-70); 0-575 ml penicillin (200 u/ml); 0-375 ml streptomycin (200 u/ml); 4 9 g NaH CO3; 190 ml unheated foetal calf serum. After mixing the medium and agar, sufficient 2-mercaptoethanol was added to produce a final molar concentration of 5 x 10-5.
The required number of spleen cells was added to the agar-medium mixture and 1-ml volumes pipetted into each Petri dish. Cultures were allowed to gel firmly at room temperature for 10-20 min, then incubated for 7 days at 37°C in a fully humidified atmosphere of 10% CO2 in air.
B-lymphocyte colony formation is dependent on the use of an adequate batch of foetal calf serum (FCS) and 6 of 9 batches tested did not support colony formation. Most of the present experiments were performed using a single batch, but for some experiment$ a second batch of foetal calf serum was used, and with this second batch it was necessary to change from the 15% FCS used in the above formula to 5% FCS to obtain comparable colony formation in control cultures.
Colony counts.-Colony counts were made in the conventional manner using an Olympus dissection microscope at x 35 magnifications and semi-indirect lighting. Discrete aggregates of 50 or more cells were scored as colonies.
Serum assays.-Batches of 20-30 human sera were tested in each assay. For each test, 0 1-ml volumes of the serum, diluted 1: 1, 1 : 4 and 1: 16 in normal saline, were pipetted to duplicate culture dishes before the addition of the cell suspension in agar medium. The serum was carefully mixed with the agar medium before gelling occurred.
In each set of assays, 3 types of controls were used (a) negative controls: 4 dishes containing 0 1 ml of normal saline, (b) positive controls: 4 dishes containing 0 1 ml of 10% washed sheep red cells, and (c) serum controls: 3 human sera used as controls in all experiments. For each of these control sera, duplicate dishes were prepared containing 0.1 ml of the serum diluted in two-fold dilutions from 1: 1 to 1: 2048.
Because of the deliberate use of low numbers of cultured cells to obtain suboptimal culture conditions (Metcalf et al., 1975b) some fluctuation occurred between different experiments in the level of Blymphocyte colony formation obtained in the control cultures. Preliminary studies in 10 control experiments showed that cultures of 25,000 C57BL spleen cells usually produced 10 ± 5 colonies with the addition of 041 ml of normal saline, 150-250 colonies with the addition of 041 ml of 10% sheep red cells, and 10-20 colonies with 041 ml of the 3 control human sera (usually at a dilution between 1 : 4 and 1 : 16). Where control values for a particular assay experiment deviated from these predetermined control values, a correction factor was applied to all colony counts from that particular experiment. This correction factor varied from 0 5 to 2-0. In the 31 assay experiments producing the data to be described, correction factors were applied to the data from 11 experiments. The control data from the remaining experiments fell within the expected range and the data from these experiments were used uncorrected. On 4 other occasions, assays failed twice due to incubator failure and twice due to contamination of media, and these assays were repeated.
Endotoxin assays-.Assays for endotoxin in the human sera were based on the fact that injection of as little as 041 ig endotoxin i.v.
to adult C57BL mice causes a rise in serum GM-CSF levels at 3 h, as assayed onmouse bone marrow cultures (Metcalf, 1971) . Pairs of 3-month-old C57BL mice were injected i.v. with 0-2 ml of the human serum to be tested, and 3 h later the mice were killed and bled. GM-CSF levels in these mouse sera were assayed in cultures of 75,000 C57BL marrow cells, using duplicate cultures containing 0.1 ml of 1: 6, 1: 18 and 1: 54 dilutions of the sera (Metcalf, 1971 ).
Classification of patients-.The sera analysed in the present study were kindly supplied by the staffs of the LeukaemiaLymphoma Clinics of the following Melbourne hospitals: Royal Melbourne Hospital, Peter MacCallum Clinic, Alfred Hospital, Austin Hospital and St Vincent's Hospital. Sera were derived from portions of blood samples being collected for routine clinical purposes. No selection of patients was made. All patients were adults and each was tested on only a single occasion. Clinical data on these patients were collected after the assays had been completed and were compiled without knowledge of the assay results. All patients had been classified following bone marrow and/or histopathological examination. In general, the criteria used for the classification and staging of patients were those of Hayhoe (1968) for the leukaemic patients and those of Lukes (1968) for the lymphoma patients.
RESULTS

General effects of human serum
Cultures of 25,000 C57BL spleen cells exhibit some B-lymphocyte colony formation in the presence of 2-mercaptoethanol, but the number of colonies developing is below that expected if a linear relationship existed between cell numbers cultured and the number of colonies developing (Metcalf et al., 1 975b) . Thus, in 10 experiments in which control cultures contained 0X1 ml normal saline, the mean number of colonies developing was 10 + 5. In cultures containing 0a1 ml of 10% fresh sheep red cells, colony formation is potentiated and becomes linear with respect to the number of cells cultured (Metcalf et al., 1975b) . Thus, in the above experiments, a mean of 207 ± 93 colonies was observed in cultures containing 0-1 ml of 10% sheep red cells.
The addition of undiluted normal human serum to cultures containing 25,000 spleen cells and 2-mercaptoethanol either completely inhibited colony formation or, as is shown in the 2 examples in Fig. 1 , reduced colony numbers below those obtained in control cultures containing saline. On progressive dilution, normal human serum lost this inhibitory activity and between dilutions of 1: 4 and 1: 16 many sera slightly increased colony numbers above control levels. Dilution of serum beyond this point failed to influence colony numbers.
In contrast to this response to normal serum, the addition of undiluted serum from certain patients, e.g. with lymphocytic lymphomas as shown in Fig. ] , caused moderate to strong stimulation of colony formation. On dilution, this stimulating activity was progressively reduced, and usually was no longer apparent at dilutions ranging between 1: 16 and 1 : 128.
Colonies developing in the presence of human serum had the gross morphology of typical B-lymphocyte colonies. Morphological examination of colony cells showed that they were mononuclear cells, many of which were identifiable as early plasma cells. Analysis of membrane immunoglobulin showed that the majority of colony cells reacted positively with a fluorescein-conjugated anti-it serum, which is again typical of B-lymphocyte colony cells (Metcalf et al., 1975b) . so Spleen populations contain some granulocytic and macrophage progenitor cells, and many of the human sera tested contained high levels of GM-CSF. However the frequency of GM-colony-forming cells in C57BL spleens is low (3/105 cells) and only occasional macrophage colonies were observed in the present cultures containing human serum. These macrophage colonies *ere readily distinguishable from B-lymphocyte colonies because of the large size of the macrophage colony cells.
Survey of human sera
Based on these observations, a simplified protocol was adopted, in which sera were tested at only 3 dilutions-I : 1, 1 : 4 and 1: 16. The results of this survey are summarized in Tables I and II , which present data only from cultures containing 0.1 ml of undiluted sera, which showed the maximum difference between normal and abnormal sera.
Sera from only 12 of 119 normal blood donors stimulated colony formation above the basal levels occurring in cultures containing saline (> 10 colonies per culture). In fact, most undiluted, normal sera inhibited colony formation, and with 51 of the sera, colony formation was completely suppressed, and only an occasional viable cell was present in the culture dishes.
Sera from patients with miscellaneous non-neoplastic diseases of haemopoiesis, such as haemolytic anaemia, iron deficiency or pernicious anaemia, and druginduced neutropenia, behaved in a similar manner to sera from normal blood donors, and only 2 of 47 sera stimulated colony formation (Table I) . As shown in Table I , approximately half of the sera tested from patients with histiocytic lymphoma, Hodgkin's disease or lymphocytic lymphoma stimulated Blymphocyte colony formation. Although the number of patients surveyed was too small to permit a realistic statistical analysis, the data suggested strongly that in each disease, serum activity was related to the stage of the disease. Few sera from Stage I and II patients stimulated colony formation and sera from patients in remission less frequently showed colony formation than sera from Stage III and IV patients (Table III) . These differences were also seen in the data on mean colony numbers in cultures containing sera from the various subgroups of patients (Table  IV) . It can also be seen from Tables III and IV that sera from Stage IV patients with histiocytic lymphoma were the most highly active of all sera analysed in the survey. In contrast to the sera from patients with lympho-proliferative diseases, only 6 of 19 sera from patients with multiple myeloma showed colony stimulating activity, and 2 of these were from patients with associated severe renal disease. The overall activity of these sera was also low, as assessed from colony numbers in cultures containing 041 ml of sera (mean colony number -13; range 0-84). A similar low activity was observed with sera from patients with chronic lymphoid leukaemia (4/20 active; mean colony number 7; range 0-48.) Very few sera were available for testing from adult patients with acute lymphoid leukaemia and, of these, 7 of 15 showed colony stimulating activity. On analysis of the clirLical data an interesting correlation emerged. Of 5 sera taken from patients prior to chemotherapy, none was active. Conversely, 7 of 8 sera known to have been taken after initiation of chemotherapy were active in stimulating colony formation. One serum sample was from a patient in long term remission and was inactive.
In (Moore et al., 1974) of the leukaemic cells in standard agar cultures with peripheral blood underlayers.
The activity was determined of sera from patients with a number of different diseases not involving haemopoietic tissues. These data are shown in Table II , in which it can be seen that sera from none of these patient groups exhibited any higher colony stimulating activity than that observed with normal serum. Of particular interest, in view of the apparent effect of chemotherapy on serum activity from acute leukaemic patients, was the fact that serum from cancer patients on roughly comparable chemotherapy failed to exhibit elevated stimulating activity. It is also noteworthy that sera from patients with a variety of autoimmune diseases, some on cytotoxic drugs, also failed to show elevated colony stimulating activity.
Overall, the results with sera from 307 patients with leukaemia or lymphomas (440o active) differed sharply from the results with sera from 232 patients with non-malignant disorders of haemopoiesis or non-haemopoietic diseases (6%o active).
Because of the availability of culture systems for assaying GM-CSF in human sera, parallel assays of individual sera were performed on C57BL marrow cells (75,000 cells/ml) for GM-CSF and on C57BL spleen cells for their capacity to stimulate B-lymphocyte colony formation. In all, 100 sera were assayed in parallel, and the results of a typical set of assays are shown in Fig. 2 . From the data for the 24 sera shown in Fig. 2 , it can be seen that only one serum (from a patient with lymphocytic lymphoma) showed both elevated GM-CSF levels and B-lymphocyte stimulating activity. For the remainder there was no correspondence whatsoever between the 2 assays, which were clearly measuring different factors in the serum. In previous work on B-lymphocyte colony formation, addition of either endotoxin or intact red cells was shown to potentiate colony formation (Metcalf et al., 1975b; Metcalf, 1976) . Since some of the sera tested were known to have come from patients with incidental infections, some sera might have contained endotoxin. Several observations made this possibility unlikely as the explanation of the observed stimulating effects of serum. The endotoxin effect is only observed with particular batches of foetal calf serum and, with the 2 batches used, addition of 20 ug endotoxin per culture failed to potentiate colony formation. Assays for endotoxin were made in C57BL mice on 15 sera with high colony stimulating activity for B-lymphocytes. Although the in vivo assay system is capable of detecting 0-1 jug endotoxin (Metcalf, 1971) no detectable endotoxin was observed in any of the 15 sera.
Some of the sera tested contained small numbers of intact red cells, and many sera were haemolysed. On visual inspection of the 665 sera tested, no correlation was observed between the degree of haemolysis in the serum and colony stimulating activity. This was formally confirmed by measurement of haemoglobin levels in 38 unselected sera.
Haemoglobin concentrations varied from 5 to 162 mg/100 ml but showed no correlation with observed colony stimulating activity (Fig. 3) . Calculation showed that 01 ml of serum with a haemoglobin level of 100 mg/100 ml contained the lysed products of approximately 3 x 106 red cells. As shown in Table V , the addition of approximately the same number of human red cells was capable of stimulating colony formation to the same degree as observed with many active sera. However, two observations make red cells unlikely to be the cause of the colony stimulation observed with some sera. Normal serum inhibited the stimulating effects of red cells, and when red cells were suspended in normal serum, little colony stimulation was observed. Finally, in the vast majority of sera tested, no intact red cells were present, only haemolysed products. It was found that osmotic haemolysis, or a single cycle of freeze-thawing (Table V) destroyed the capacity of red cells to potentiate colony formation. In contrast, the colony stimulating activity of serum was retained after freeze-thawing.
A final possibility investigated was based on the report (Adler et al., 1970) that the ability of human sera to support PHAstimulated proliferation of mouse Tlymphocytes is due to the presence of antimouse-red-cell haemagglutinins. Haem- Titration of normal serum showed that most undiluted sera actually inhibited colony formation but, on dilution, many of these sera showed low levels of stimulating activity. The observed stimulating activity of undiluted sera from patients with lymphoproliferative diseases suggests that these sera may contain elevated levels of a factor capable of stimulating Blymphocyte proliferation. In addition, such sera either lack the inhibitory material present in normal sera, or this inhibitory activity is overridden by the high stimulating activity. Further experiments on fractionated sera will be required to determine which of these possibilities is correct.
In individual sera, colony stimulating activity for B-lymphocytes was not correlated with capacity to stimulate granulocytic and macrophage colony formation by mouse bone marrow cells, and the active factor therefore appears not to be GM-CSF. Experiments have also made it improbable that the B-lymphocytestimulating activity of the sera is due to endotoxin or red cells, two factors known to be capable of stimulating B-lymphocyte colony formation (Metcalf et al., 1975b; Metcalf, 1976) .
It was of interest that stimulating activity was low or not demonstrable in serum from patients with 3 types of Blymphocyte disorders-multiple myeloma, chronic lymphoid leukaemia and autoimmune diseases. These obervations are unexpected if the observed stimulation is due to a B-lymphocyte-specific factor, and the situation needs further investigation. While most sera from pretreatment patients with acute lymphoid or myeloid leukaemia failed to stimulate colony formation, a high proportion of sera from patients on chemotherapy showed moderate colony stimulating activity. This strongly suggested that the active serum factor might have originated from druginduced breakdown of normal or leukaemic cells. While this remains a possible explanation, colony stimulating activity was not observed in sera from cancer patients under treatment with a variety of cytotoxic drugs.
The correlation observed in patients with lymphoproliferative disorders, between disease stage and serum activity, is also consistent with an origin of the active factor from the breakdown of either the tumour population or reacting host cells. In view of the effect of chemotherapy on serum activity in acute leukaemia, the role of chemotherapy in the high serum activity seen in Stage III and IV patients needs further investigation. Preliminary data from individual patients studied sequentially suggest that the observed serum activity is unlikely to be due to the presence of cytotoxic drugs per se in the serum. However, an active factor produced or released as a consequence of drug action remains a possibility. Since elevated serum activity was not observed early in these diseases, it seems unlikely that the factor being detected plays a significant role in the development of these diseases.
The observation that sera from patients with lymphoproliferative disorders can stimulate lymphocyte proliferation in vitro, raises the possibility that what is being detected is analogous with the lymphocyte-stimulating factors released in vitro by mitogen-activated lymphocytes (Kasakura and Lowenstein, 1965; Dutton et al., 1971) . However, the significance of the present observations cannot be determined until further analytical studies are performed on the nature and origin of the active serum component. The present agar cloning system appears to be a useful technique for use in further studies on this phenomenon.
